Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/S1473-3099(21)00263-2 http://scihub22266oqcxt.onion/10.1016/S1473-3099(21)00263-2 34019801!8131060!34019801     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Lancet+Infect+Dis 2021 ; 21 (11): e342-e347 Nephropedia Template TP {{tp|p=34019801|t=2021. Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities |pdf=|usr=}}{{34019801}} gab.com Text Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities JO: Lancet Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=34019801 #FOAvip Large-scale deployment of COVID-19 vaccines will seriously affect the ongoing phases 2 and 3 randomised placebo-controlled trials assessing SARS-CoV-2 vaccine candidates. The effect will be particularly acute in high-income countries where the entire adult or older population could be vaccinated by late 2021. Regrettably, only a small proportion of the population in many low-income and middle-income countries will have access to available vaccines. Sponsors of COVID-19 vaccine candidates currently in phase 2 or initiating phase 3 trials in 2021 should consider continuing the research in countries with limited affordability and availability of COVID-19 vaccines. Several ethical principles must be implemented to ensure the equitable, non-exploitative, and respectful conduct of trials in resource-poor settings. Once sufficient knowledge on the immunogenicity response to COVID-19 vaccines is acquired, non-inferiority immunogenicity trials-comparing the immune response of a vaccine candidate to that of an authorised vaccine-would probably be the most common trial design. Until then, placebo-controlled, double-blind, crossover trials will continue to play a role in the development of new vaccine candidates. WHO or the Council for International Organizations of Medical Sciences should define an ethical framework for the requirements and benefits for trial participants and host communities in resource-poor settings that should require commitment from all vaccine candidate sponsors from high-income countries. Twit Text FOAVip Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities ????Lancet Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=34019801 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34019801 #FOAvip English Wikipedia <ref>{{Cite pmid|34019801}}</ref> Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities #MMPMID34019801 Dal-Re R; Bekker LG; Gluud C; Holm S; Jha V; Poland GA; Rosendaal FR; Schwarzer-Daum B; Sevene E; Tinto H; Voo TC; Sreeharan N Lancet Infect Dis 2021[Nov]; 21 (11): e342-e347 PMID34019801show ga Large-scale deployment of COVID-19 vaccines will seriously affect the ongoing phases 2 and 3 randomised placebo-controlled trials assessing SARS-CoV-2 vaccine candidates. The effect will be particularly acute in high-income countries where the entire adult or older population could be vaccinated by late 2021. Regrettably, only a small proportion of the population in many low-income and middle-income countries will have access to available vaccines. Sponsors of COVID-19 vaccine candidates currently in phase 2 or initiating phase 3 trials in 2021 should consider continuing the research in countries with limited affordability and availability of COVID-19 vaccines. Several ethical principles must be implemented to ensure the equitable, non-exploitative, and respectful conduct of trials in resource-poor settings. Once sufficient knowledge on the immunogenicity response to COVID-19 vaccines is acquired, non-inferiority immunogenicity trials-comparing the immune response of a vaccine candidate to that of an authorised vaccine-would probably be the most common trial design. Until then, placebo-controlled, double-blind, crossover trials will continue to play a role in the development of new vaccine candidates. WHO or the Council for International Organizations of Medical Sciences should define an ethical framework for the requirements and benefits for trial participants and host communities in resource-poor settings that should require commitment from all vaccine candidate sponsors from high-income countries. |*Clinical Trials as Topic[MESH] |COVID-19 Vaccines/administration & dosage/*immunology[MESH] |COVID-19/epidemiology/immunology/*prevention & control/virology[MESH] |Double-Blind Method[MESH] |Humans[MESH] |Immunogenicity, Vaccine[MESH] |Pandemics/prevention & control[MESH]Ongoing and future COVID-19 vaccine clinical trials: challenges and o(epmc).pdf DeepDyve Pubget Overpricing